The pipeline data presented in this report helps executives for tracking competition, identifying partners, evaluating opportunities, formulating business development strategies, and executing in-licensing and out-licensing deals.
The report presents pipeline by Gastrointestinal Disorders indications. Key indications covered in this report include Gastro-esophageal reflux disease (GERD), Gastric ulcer, Peptic ulcer, Crohn's disease, Ulcerative colitis, and Irritable bowel syndrome.
By Clinical Trial Stages:
The report provides Gastrointestinal Disorders pipeline molecules by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.
By Drug Mechanism Classes:
The report provides Gastrointestinal Disorders pipeline molecules by their dominant drug mechanism class. This helps executives categorize molecules based on their drug class and also assess the strengths and weaknesses of compounds.
The report provides Gastrointestinal Disorders pipeline molecules by the developing company and the partnered company.
- Gastrointestinal Disorders Pipeline by Indication
- Gastrointestinal Disorders Pipeline by Clinical Trial Phase
- Gastrointestinal Disorders Pipeline by Drug Mechanism Classes
- Gastrointestinal Disorders Pipeline by Company